Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,015 across all filing types
Latest filing 2026-06-10 Regulatory Filings
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 27% confidence The document is an SEC Form 6-K—a report of a foreign private issuer—submitted under Exchange Act rules, containing a reference to an attached ASX CEO Connect presentation as Exhibit 99.1. It does not itself contain substantive financial statements or presentation content, but is a regulatory filing to the SEC. Therefore it falls under the catch-all category for general regulatory announcements and filings: Regulatory Filings (RNS).
2026-06-10 English
ASX CEO Connect Presentation 13 pages 1.4MB
Investor Presentation Classification · 93% confidence The document is a slide-based presentation with forward-looking statements, detailed pipeline overviews, financial highlights, and strategic milestones aimed at investors (e.g., ASX CEO Connect Presentation, slide numbers, charts, bullet points). It is not a formal earnings release, annual report, or regulatory filing but a marketing/investor deck. Therefore, it fits the definition of an Investor Presentation.
2026-06-02 English
6-K - MESOBLAST LTD (0001345099) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mesoblast Limited, pursuant to SEC rules. It references the filing of a quarterly report (Appendix 4C) for the quarter ended March 31, 2026, which is attached as an exhibit. The document itself is only 1705 characters long and primarily serves as a cover report to submit the quarterly report to the SEC. It does not contain substantive financial data or analysis itself but refers to the quarterly report filed with the Australian Securities Exchange. According to the MENU VS MEAL RULE, this document is an announcement or cover filing rather than the actual quarterly report. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for such filings that do not contain the full report content.
2026-04-30 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 591.1KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement from Mesoblast Limited providing a quarterly activity report for the quarter ended March 31, 2026. It includes financial highlights such as net revenues, net operating cash spend, and cash balances. It also discusses operational highlights including clinical trial progress and R&D activities. The document contains an Appendix 4C, which is a quarterly cash flow report required by ASX Listing Rule 4.7B. The Appendix 4C includes detailed cash flow statements for operating, investing, and financing activities for the quarter and year to date. The presence of the Appendix 4C cash flow report and the detailed financial data for the quarter indicates this is a comprehensive interim/quarterly financial report rather than a brief earnings release or a simple announcement. The document is about 15,000 characters long, which supports it being a full report rather than a short announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2026
2026-04-29 English
6-K - MESOBLAST LTD (0001345099) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed pursuant to SEC rules. It references a press release filed with the Australian Securities Exchange as Exhibit 99.1. The document length is only 1613 characters, indicating it is a short filing primarily serving as a cover report and reference to the attached press release. There is no substantive financial data or detailed report content within this document itself. According to the rules, such short filings that announce or attach other reports or releases should be classified as Regulatory Filings (RNS).
2026-04-29 English
Patient Recruitment Target Achieved in CLBP Pivotal Trial 3 pages 265.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Mesoblast Limited about achieving patient recruitment targets in a pivotal Phase 3 clinical trial for a drug candidate. It discusses clinical trial progress, regulatory designations, expected timelines for top-line results, and potential future regulatory filings. There are no financial statements, detailed financial performance data, or comprehensive management analysis. The document is a corporate announcement about clinical trial progress and regulatory milestones rather than a financial report or earnings release. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing in the sense of officer certifications or compliance documents, nor is it a report publication announcement. The content is best classified as a general regulatory announcement about clinical trial progress and regulatory status, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other categories.
2026-04-28 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.